GlassScriptPhysician profile
An Duy Le
NPI 1215377841
$5,740.95
in general payments reported to CMS, 2019-2025
14 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,324 · 2020: $938 · 2021: $863 · 2022: $711 · 2023: $423 · 2024: $353 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $905.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $2,271.52 | 2019-2025 | Grafix, Stravix Pl, Oasis |
| Zimmer Biomet Holdings, INC. | $1,326.31 | 2019-2021 | |
| Organogenesis INC. | $725.02 | 2019-2024 | Puraply, Puraply Wound Matrix, Apligraf |
| Stryker Corporation | $513.15 | 2019-2024 | Variax, Citrefix, Ortholoc 3di |
| Osiris Therapeutics INC. | $355.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $173.78 | 2019-2022 | |
| Paragon 28, INC. | $147.60 | 2022 | |
| Kerecis Limited | $56.69 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Nextremity Solutions INC. | $55.01 | 2019 | |
| Integra Lifesciences Corporation | $40.80 | 2019 | |
| Reapplix INC. | $27.59 | 2025 | 3c Patch Kit - Box |
| Paratek Pharmaceuticals, INC. | $19.96 | 2024 | Nuzyra |
| Melinta Therapeutics, LLC | $14.36 | 2022 | |
| Aroa Biosurgery Incorporated | $13.17 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw An Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.